Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902928 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
A Phase 2 study, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 1,992
- Enrollment target
NCT00902928 is a Phase 2 study that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 1,992 participants.
The verdict
NCT00902928, a Phase 2 study, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,992 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.
Interventions
- DRUG enoxaparin
- DRUG YM150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,992 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00902928
The ClinicalTrials.gov registry entry for NCT00902928 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,992 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe B.V., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which enoxaparin is the first listed.
NCT00902928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00902928 about?
NCT00902928 is a clinical study titled "A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery". The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.
What is the current status of trial NCT00902928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,992 participants. The study started on 2009-04. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00902928?
The interventions under investigation include: enoxaparin (DRUG), YM150 (DRUG).
Who is sponsoring clinical trial NCT00902928?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.